

Medtronic Hires Renowned Cardiologist as Vice President of Medical Affairs for Coronary and Peripheral Business

*MEDTRONIC HIRES RENOWNED CARDIOLOGIST AS VICE PRESIDENT OF MEDICAL AFFAIRS FOR CORONARY AND PERIPHERAL BUSINESS*

*Researcher, Educator and Innovator Prof. Martin Rothman Assumes New Role with Industry Following 37 Years of Clinical Practice*

Medtronic, Inc. (NYSE: MDT), today announced the hire of Prof. Martin Rothman as vice president of medical affairs for the company's coronary and peripheral vascular business based in Santa Rosa, Calif.

Prof. Rothman will join Medtronic on Jan. 4, 2010, after 37 years of clinical practice in the U.K. as an interventional cardiologist, including 27 years at the London Chest Hospital (Barts and the London NHS Trust), where he has served for more than a decade as director of cardiac research and development. He is world renowned for his contributions to clinical research, training and education, and medical technology innovation in cardiovascular medicine.

"Prof. Rothman stands out as a pioneer and leader in interventional cardiology," said Sean Salmon, vice president and general manager of the Coronary and Peripheral division, part of the CardioVascular business, at Medtronic. "We look forward to his leadership of our office of medical affairs, which will benefit from the scientific rigor and keen insights that he has demonstrated throughout his medical career."

A regular presenter at medical meetings and author of peer-reviewed journal articles, Prof. Rothman has conducted scores of clinical trials related to interventional cardiology. He has participated as an investigator in studies of Medtronic's Endeavor(R) drug-eluting coronary stents. In addition, Prof. Rothman has led cardiac stem cell research for heart failure treatment. He also established the largest heart attack center in Europe.

During his tenure at the London Chest Hospital, Prof. Rothman developed a nationally and internationally recognized training program for interventional cardiology, a medical specialty that treats patients with heart disease through minimally invasive techniques such as angioplasty and transcatheter valves. Prof. Rothman has contributed significantly to advancing the specialty's medical education, including the development of live case demonstrations, which enable clinicians to learn through observation and interaction with the physicians performing the procedures. Under his leadership of this training program, the London Chest Hospital has trained more than 500 interventional cardiologists each year. More than one-third of practicing interventional cardiologists in the U.K. have been trained by Prof. Rothman.

Prof. Rothman has also contributed to the development of innovative medical technology for interventional cardiology. In 1985 he created his first start-up company, which developed intravascular ultrasound technology to enable clinicians to see inside their patients' arteries. He sold the company in May 2000. Intravascular ultrasound is now routinely used in clinical research and practice.

The CardioVascular business at Medtronic is committed to advancing the treatment of coronary, peripheral, aortic and structural heart disease through collaboration with leading clinicians, researchers and scientists worldwide.

About Medtronic

Medtronic, Inc. ([http://cts.businesswire.com/ct/CT?](http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.medtronic.com%2F&esheet=6110842&lan=en_US&anchor=www.medtronic.com&index=1&md5=1ed23fe9faa9912aad98902c04c28fd8)

[id=smartlink&url=http%3A%2F%2Fwww.medtronic.com%2F&esheet=6110842&lan=en\\_US&anchor=www.medtronic.com&index=1&md5=1ed23fe9faa9912aad98902c04c28fd8](http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.medtronic.com%2F&esheet=6110842&lan=en_US&anchor=www.medtronic.com&index=1&md5=1ed23fe9faa9912aad98902c04c28fd8)), headquartered in Minneapolis, is the global leader in medical technology - alleviating pain, restoring health and extending life for millions of people around the world.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's Annual Report on Form 10-K for the year ended April 24, 2009. Actual results may differ materially from anticipated results.

SOURCE: Medtronic, Inc.

Medtronic, Inc.  
Joe McGrath, 707-591-7367  
Public Relations  
or  
Jeff Warren, 763-505-2696  
Investor Relations

---

<https://news.medtronic.com/2009-12-08-Medtronic-Hires-Renowned-Cardiologist-as-Vice-President-of-Medical-Affairs-for-Coronary-and-Peripheral-Business>